Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 27 March 2012
Vol. 5, Issue 217, p. ec98
[DOI: 10.1126/scisignal.2003067]

EDITORS' CHOICE

Alzheimer's Disease Reversing Decline?

Stella M. Hurtley

Science, AAAS, Cambridge CB2 1LQ, UK

Apolipoprotein E (apoE) normally helps in the clearance of β-amyloid (Aβ) from the brain, a process that is compromised in Alzheimer’s disease. Cramer et al. (see the Perspective by Strittmatter) now show that a drug that increases apoE expression rapidly promoted soluble Aβ clearance in a mouse model of Alzheimer’s disease. The drug also improved cognitive, social, and olfactory performance and rapidly improved neural circuit function. Similar therapeutics may potentially help to ameliorate the symptoms of Alzheimer’s disease and its prodromal states.

P. E. Cramer, J. R. Cirrito, D. W. Wesson, C. Y. D. Lee, J. C. Karlo, A. E. Zinn, B. T. Casali, J. L. Restivo, W. D. Goebel, M. J. James, K. R. Brunden, D. A. Wilson, G. E. Landreth, ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503–1506 (2012). [Abstract] [Full Text]

W. J. Strittmatter, Old drug, new hope for Alzheimer’s disease. Science 335, 1447–1448 (2012). [Abstract] [Full Text]

Citation: S. M. Hurtley, Reversing Decline? Sci. Signal. 5, ec98 (2012).



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882